Home » Final NICE ‘No’ for Pfizer’s Xalkori
Final NICE ‘No’ for Pfizer’s Xalkori
The UK’s NICE has decided that patients with advanced non-small-cell lung cancer will not have access to Pfizer’s Xalkori through the National Health Service, claiming the drug does not provide enough value for money.
Pharma Times
Pharma Times
Upcoming Events
-
07May
-
14May
-
30May